- Home
- RCG vs IMRN Comparison
RCG vs IMRN Comparison
Compare RCG & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCG
- IMRN
- Stock Information
- Founded
- RCG 1994
- IMRN 1994
- Country
- RCG United States
- IMRN Australia
- Employees
- RCG N/A
- IMRN N/A
- Industry
- RCG Investment Managers
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- RCG Finance
- IMRN Health Care
- Exchange
- RCG Nasdaq
- IMRN Nasdaq
- Market Cap
- RCG 15.6M
- IMRN 15.0M
- IPO Year
- RCG N/A
- IMRN N/A
- Fundamental
- Price
- RCG $2.37
- IMRN $1.91
- Analyst Decision
- RCG
- IMRN Strong Buy
- Analyst Count
- RCG 0
- IMRN 1
- Target Price
- RCG N/A
- IMRN $5.00
- AVG Volume (30 Days)
- RCG 5.9K
- IMRN 6.4K
- Earning Date
- RCG 01-01-0001
- IMRN 12-03-2024
- Dividend Yield
- RCG 0.98%
- IMRN N/A
- EPS Growth
- RCG N/A
- IMRN N/A
- EPS
- RCG N/A
- IMRN N/A
- Revenue
- RCG N/A
- IMRN $3,271,194.00
- Revenue This Year
- RCG N/A
- IMRN N/A
- Revenue Next Year
- RCG N/A
- IMRN N/A
- P/E Ratio
- RCG N/A
- IMRN N/A
- Revenue Growth
- RCG N/A
- IMRN 171.67
- 52 Week Low
- RCG $1.52
- IMRN $1.59
- 52 Week High
- RCG $1.90
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- RCG 67.56
- IMRN 45.34
- Support Level
- RCG $2.31
- IMRN $1.81
- Resistance Level
- RCG $2.34
- IMRN $1.99
- Average True Range (ATR)
- RCG 0.04
- IMRN 0.13
- MACD
- RCG 0.00
- IMRN 0.02
- Stochastic Oscillator
- RCG 95.00
- IMRN 46.71
About RCG RENN Fund Inc
RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, Oil and Gas, medical chemicals, botanical products, and others.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.